Category health

National,10^th May 2025: PRIVÉ LUXE Skin and Wellness Clinic, the luxury wellness space founded by celebrated dermatologists and cosmetologist Dr. Amit Bhasin and Dr. Aarti Bhasin, has announced the grand opening of its second clinic at Vasant Vihar, Delhi. The new space marks a bold evolution in the clinic’s vision—offering not just skincare, but a transformative, holistic approach to health and beauty rooted in science, empathy, and results.

The new clinic introduces India’s first authentic Korean PDRN + Exosome therapy, a regenerative treatment that is rapidly gaining popularity across Asia for its ability to heal damaged skin, improve texture, and deeply hydrate at a cellular level. PDRN (Polydeoxyribonucleotide), derived from salmon DNA, is renowned for its skin-repairing and rejuvenating properties. Combined with Exosomes—nano-sized messengers rich in growth factors and peptides—this treatment provides extraordinary results in skin regeneration, collagen stimulation, pigmentation reduction, and anti-ageing.

“At PRIVÉ luxe, we believe true luxury lies in feeling your best—inside and out,” says Dr. Amit Bhasin, Managing Director of PRIVÉ Luxe and a leading voice in Indian dermatology. “PDRN + Exosomes represent a   breakthrough in skin healing, and we are proud to be the first in India to introduce the authentic Korean formulation. My expertise has always focused on achieving results that enhance one’s natural features—subtle, refined, and true to everyone’s unique beauty.”

Dr. Aarti Bhasin, CEO, PRIVÉ Luxe added, “What makes PRIVÉ special is the way we combine precision with empathy. We don’t believe in one-size-fits-all treatments. Every individual’s skin tells a story, and our role is to listen carefully before deciding how best to support it. PDRN fits beautifully into this philosophy — it is gentle, effective and works in harmony with the skin rather than overpowering it. We are proud to be the first to introduce it in India the way it is meant to be experienced.”

Privé Skin Clinic goes beyond conventional dermatological services by embracing a philosophy rooted in holistic wellness. Rooted in the belief that external radiance stems from internal balance, the clinic’s Skin & Wellness philosophy combines advanced dermatological treatments with clinical dietetics, physiotherapy, psychology, Ayurveda, internal medicine, and even aesthetic plastic surgery. Each patient’s journey is mapped with intention, addressing not just visible symptoms but also the deeper, often overlooked causes, ranging from hormonal imbalances to gut health and emotional well-being.

Staying true to its ethos of elegance and restraint, PRIVÉ delivers refined, natural-looking results that focus on restoration, not transformation. Every treatment, whether a regenerative facial, laser therapy, injectables, or advanced anti-aging solution—is thoughtfully selected to enhance one’s features while preserving individuality. Signature offerings include HydraFacial MD, Glass Glow Facials, Skin Boosters like Hyaluronic Acid and Polynucleotides, laser resurfacing, Morpheus8, Baby Botox, PRP, and IV therapies. Blending the latest medical innovations with an aesthetic eye, PRIVÉ ensures that every procedure is grounded in intention—prioritizing subtle enhancements, long-term skin health, and the patient’s unique goals.

The launch of the new clinic is not just a milestone for the brand, but a testament to a growing shift in how wellness is being perceived in India. With its compassionate, science-backed, and artistically guided approach, PRIVÉ Luxe is leading a new movement—one that embraces natural beauty, emotional healing, and personalized care. For those seeking authentic transformation and lasting results in a truly luxurious environment, PRIVÉ Luxe is more than a clinic—it is a sanctuary for self-renewal.

Hyderabad, May 09, 2025 — GRACE (Global Research and Cancer Education) Cancer Foundation on Friday announced the 8th edition of Quambiant Developers Global Grace Cancer Run (GGCR)–2025, powered by Evernorth, the world’s largest Cancer Awareness Run, at a launch function held at Hotel Daspalla, Jubilee Hills, Hyderabad.

The theme for the edition is “Run for Grace and Screen for Life”

The run will be organised by the Hyderabad-based non-profit Grace Cancer Foundation, which has been working for 11 years to alleviate the cancer burden through Education, Early Detection, Treatment, Rehabilitation, and Research.

Dr. Alagu Varsini, IAS, Secretary, Telangana Social Welfare Residential Educational Institutions Society (TGSWREIS), was the Chief Guest, while Ms. Shilpa Reddy—Mrs. India, a model, entrepreneur, fashion designer, and socialite, graced the occasion as the Guest of Honour. The dignitaries were joined by Dr. Chinnababu Sunkavalli, Senior Consultant, Robotic Surgical Oncologist and Founder of Grace Cancer Foundation, along with a host of doctors, runners, and volunteers. Mr. Sujatha Rao, Dr Prameela China Babu, Mr. Vijay, Mr. Yogendranath, Bharanendra Nallamotu, Ashok Venkatachalam and others graced the occasion.

Addressing the gathering of over 200 participants after unveiling the event poster, Dr. Alagu Varsini said she found the initiative very genuine and a need of the hour. We have engaged 70,000 girls during the National Cancer Week to create awareness about cancer.  We will see that 10,000 girls students of the TGSWREIS participate in the run. We should talk about cancer openly and freely, she said.

Ms. Shilpa Reddy, in her remarks, said, there are a few things which are non-negotiable in life. And that good diet.  We should take the right diet.  Our food can be both poisonous and medicine.  Make food medicine by taking the right food. Avoid eating packaged food which contains a lot of preservatives and synthetics.  Another important non-negotiable thing in our lives is sleep, a good amount of sleep. Avoid taking toxins, listen to your body, she said.

Today all can’t afford to go for early detection tests of cancer.  You may gift somebody a test., she said.

In his welcome address, Dr. Chinnababu Sunkavalli shared the vision behind the event: “The Run aims to make a meaningful impact by raising cancer awareness, promoting physical activity as a preventive measure, and enabling access to free doorstep cancer screening for the underprivileged.”

The 8th Global Grace Cancer Run will take place on 12^th October, 2025 in hybrid mode—both Physical and Virtual. The physical run will be held at Gachibowli, Hyderabad, with over 30,000 to 40,000 runners, including 10,000 students from Navodaya schools, expected to be locally informed by Bharanendra Nallamotu.

The event features three race categories: 2K, 5K, and 10 K.

Participants can register (please insert URL) online by paying a nominal fee:

• ₹600 for 2K
• ₹800 for 5K
• ₹1200 for 10K

Corporate supporters include Quambiant Developers, Evernorth, and Ryan, who are backing the cause.

The proceeds will fund mobile cancer screenings for underserved communities, to screen one lakh lives for Non-Communicable Diseases (NCDS) and deliver doorstep healthcare to rural India.

Over the past 11 years, the initiative has impacted 1.4 crore people across 130 countries. The Foundation’s programs range from:

• Tribal Cancer Screening in Odisha and Araku Valley
• Cancer checks for Anganwadi staff in Telangana
• Screening for Cyberabad police personnel
• HPV vaccinations and screenings in educational institutions
• Internship programs for international students
• Collaborative research and innovations

The 7th edition drew an overwhelming 1.5 lakh runners from 130 countries, making it a truly global movement.

Join the Movement. Save Lives.

Cancer doesn’t discriminate—it can affect anyone, anywhere. By participating in the Global Grace Cancer Run–2025, you’re not just running—you’re running for a cause. Your steps will help fund free cancer screenings for thousands of underprivileged individuals, bringing hope and early detection to those who need it most. This is more than an event; it’s a global movement spanning 130 countries, driven by compassion and the commitment to fight cancer together. Let’s lace up not just for ourselves, but for the lives we can touch. Run for awareness. Run for prevention. Run for change.

Cancer is no longer a death sentence—if detected early, it is curable. Early detection is the most powerful weapon we have. Regular screenings and awareness can save lives. Awareness is the first step toward prevention and cure. Many lives are lost not because of cancer, but because it was discovered too late.  You may not run for yourself, but you can run for someone who can’t. Every step you take helps bring screening and care to people who otherwise have no access. 1 in 9 Indians is at risk of developing cancer in their lifetime. Participation in awareness initiatives like this run can make a real difference in shifting that statistic, Dr. Chinna Babu added in his closing remarks.  

Please log in to www.gracecancerrun.com for online registration.

Hyderabad, May 9, 2025: Apollo Hospitals Jubilee Hills proudly announces a historic medical milestone – Dr. Rooma Sinha, Senior Consultant in Gynaecology and Robotic Surgery, has successfully performed over 1,000 robotic surgeries for benign Gynaecological conditions, making her India’s highest-volume single surgeon in this field.

Specializing in the treatment of complex fibroids and advanced endometriosis, Dr. Sinha has become a globally recognized name in robotic-assisted gynaecology. This achievement represents not only a personal surgical feat but also a transformative leap in minimally invasive, fertility-preserving care for women in India.

“This achievement underscores Apollo’s position as the premier destination for robotic surgery in India,” said Dr. Sangita Reddy, Joint Managing Director, Apollo Hospitals Group. “Dr. Rooma Sinha’s journey exemplifies how technology and empathy can converge to transform women’s health.”

“Apollo Jubilee Hills continues to raise the bar in adopting path-breaking technologies. Dr. Sinha’s achievement is not only a triumph of skill but also of vision. She is helping make robotic gynaecology mainstream in India,” said Mr. Tejesvi Rao, CEO, Apollo Hospitals, Telangana Region.

On this occasion, Dr. Rooma Sinha stated: “In India, fibroids affect an estimated 25–50% of reproductive-age women, while up to 10% suffer from endometriosis—conditions that often lead to infertility, chronic pelvic pain, and repeated surgeries. Traditional open surgeries pose significant risks, including longer recovery times and reduced fertility outcomes.”

“Recognizing the urgent need for safer, precision-based, and fertility-preserving solutions, I adopted and advanced robotic surgery to revolutionize gynaecologic care. My mission is simple: No woman should undergo open surgery when a safer, minimally invasive option exists. This milestone isn’t just mine—it belongs to every patient who trusted me, every student I’ve taught, and every woman we’ve helped to heal with dignity improving their quality of life”

She said Robotic surgery offers particular benefits in cases of advanced endometriosis, large or multiple fibroids, previous multiple surgeries, and obesity situations where traditional surgery carries higher risks. It is also increasingly used in treating uterine cancers, where robotic techniques enable greater precision and safety.

“Manipal Hospital Malleshwaram’s advanced CATH Lab reminds us how a healthy community is an integral part of our lives.” Dr. Ashwath Narayan C N, MLA, Malleshwaram, Former DCM, Karnataka stated. “With the aim to build a community that has accessibility to the best facilities, we want to take every step required for the elderly in Bengaluru.”

Dr. H Sudarshan Ballal, Chairman – Manipal Hospitals noted, “Our aim has always been to cater to every individual with proper diagnosis and timely interventions. Patient satisfaction with their requirements drives us to take more such initiatives.”

Chennai, May 9, 2025:Apollo Proton Cancer Centre (APCC), Chennai, has reaffirmed its leadership in comprehensive cancer care with the launch of a dedicated Bone Marrow Transplant (BMT) unit, inaugurated on World Thalassaemia Day. This milestone further strengthens APCC’s ability to deliver holistic cancer care—from cutting-edge radiation therapies such as Total Marrow and Lymphoid Irradiation (TMLI) to advanced hematology and transplant services—offered collaboratively by multidisciplinary teams in one integrated centre.

The BMT unit was officially inaugurated by Dr. TRB Rajaa, Hon’ble Minister for Industries, Investment Promotion & Commerce, Government of Tamil Nadu. He was joined by senior leadership from Apollo Hospitals, including Mr. Dinesh Madhavan, President, Group Oncology and International, and Mr. Harshad Reddy, Director, Group Oncology and International. Other dignitaries present included Dr. Jose Easow, Director – Medical Oncology, Hematology & BMT, Dr. Srinivas Chilukuri, Senior Consultant, Radiation Oncology, and Mr. Karan Puri, Chief Executive Officer, APCC, along with senior clinicians from the Apollo Proton Cancer Centre.

This launch places APCC among a select group of global centres offering Total Marrow and Lymphoid Irradiation (TMLI)—a state-of-the-art conditioning regimen for bone marrow transplantation. Unlike traditional Total Body Irradiation (TBI), which affects the entire body including vital organs, TMLI precisely targets marrow and lymphoid tissues while sparing healthy organs such as the heart, liver, and kidneys. This targeted approach significantly reduces treatment-related toxicity and improves clinical outcomes for patients, especially those battling leukemia and lymphoma

Chief Guest Dr. TRB Rajaa, Minister for Industries, Investment Promotion & Commerce, Government of Tamil Nadu, reaffirmed the state’s commitment to advancing healthcare, stating, “Tamil Nadu continues to foster an enabling ecosystem that encourages innovation, public-private collaboration, and equitable access to advanced treatments. Our focus on cancer detection, HPV vaccination, and the integration of cutting-edge technologies like robotic surgery and AI diagnostics in the state underlines this commitment. Institutions like Apollo Proton Cancer Centre not only set global benchmarks in cancer care but also mirror the transformative potential of our healthcare model. I congratulate the Apollo team and clinical specialists for bringing pioneering treatments like BMT and TMLI to Tamil Nadu, further strengthening the state’s position as a global healthcare destination.”

Dr. Jose Easow, Director – Medical Oncology, Hematology & Blood and Marrow Transplantation at APCC, said, “With the integration of  BMT services with TMLI and precision radiation, APCC is creating an unparalleled, patient-centric ecosystem for hematologic cancer treatment. TMLI allows us to deliver targeted conditioning with significantly reduced toxicity, leading to better outcomes and improved quality of life for transplant patients. This integration reflects our commitment to providing world-class, evidence-based care in India.”

Mr. Dinesh Madhavan, President, Group Oncology and International, Apollo Hospitals Enterprise Limited, said, “With the integration of Bone Marrow Transplant services and advanced radiation therapies like TMLI, Apollo Proton Cancer Centre reaffirms its commitment to delivering end-to-end comprehensive cancer care with global standards. Our commitment is not just about adding capabilities—it’s about ensuring that every patient, regardless of complexity, has access to personalized, cutting-edge treatment under one roof. It also reflects our unwavering vision to make India a destination for world-class personalised  oncology care.”

Dr. Srinivas Chilukuri, Senior Consultant – Radiation Oncology, Apollo Proton Cancer Centre, said, “By combining advanced BMT and TMLI, APCC is redefining care standards for complex blood cancers. Our organ-sparing approach enhances not only outcomes but also recovery and resilience post-transplant. It’s not just about technology—it’s about bringing compassionate, curative care closer to patients.”

The burden of blood-related disorders in India is alarming. According to Studies, India records over 10,000 new cases of childhood leukemia annually and is home to the largest number of children with thalassemia major—around 100,000. Around 3% to 4% of Indian population are carriers of thalassemia, while in Tamil Nadu, the incidence is estimated to be 4%. (Source Link) 

Despite BMT being the only curative treatment for several of these conditions, accessibility remains a concern. The establishment of a high-end BMT program within APCC bridges this critical gap. With the introduction of BMT and advanced TMLI radiation, APCC is now India’s most comprehensive and technologically integrated cancer centre, addressing both curative and quality-of-life dimensions of cancer care.

Apollo Hospitals has been at the forefront of making Bone Marrow Transplant (BMT) accessible across India. In 2023, Apollo Cancer Centre in Chennai was recognized for treating the highest number of 127 BMT patients out of which  24 thalassemia-affected children benefitted under the Tamil Nadu CM’s Health Scheme, offering BMT at zero cost to underprivileged families. In 2024, its Hyderabad centre launched the first outpatient BMT service in Andhra Pradesh and Telangana, enabling day-care transplant support for stable blood cancer and thalassemia patients.

Chennai, May 8, 2025: In a landmark surgical achievement, a multidisciplinary transplant team at MGM Healthcare successfully performed a complex renal re-transplant on a 12-year-old child from Lucknow, born with a rare vascular condition—classified as a V4 venous anomaly—that involved the absence of major abdominal veins and vein networks from birth.

The child had previously undergone a kidney transplant but had experienced graft failure and is waiting for the re-transplant. However, the absence of the usual venous drainage system presented a major surgical challenge. Demonstrating remarkable innovation, the surgical team identified and reused the venous pathways from the earlier transplant to ensure safe and effective placement and blood flow (perfusion) of the new graft. The old kidney graft was carefully removed while preserving the existing venous structures to facilitate the second transplant. The child is recovering well, demonstrating early graft function with no vascular or urological complications.

The surgery was led by Dr. Anil Vaidya, Chair and Director, Institute of Multi-Visceral and Abdominal Organ Transplant, MGM Healthcare, with support from a multidisciplinary team that included Dr. Sukanya Govindhan, Consultant Paediatric Nephrologist; Dr Senthil Muthuraman, Senior Consultant in Multi-Visceral and Abdominal Organ Transplant; Dr. Ram Gurajala, Interventional Radiologist; and anaesthesiologists: Dr. Dinesh Babu and Dr. Nivash Chandrasekaran.

In his comments, Dr. Ram Gurajala said, “A V4 venous anomaly is a rare condition where a child is born without the major veins (inferior vena cava and major iliac veins) in the belly and lower body that return blood to the heart. This makes surgeries like kidney transplants extremely difficult, as the usual pathways for blood flow are missing. However, we navigated this anatomical challenge by identifying and utilising the previously used venous outflow pathways, ensuring safe and effective graft placement and blood flow. This successful outcome brings renewed hope and quality of life to this young patient and family. It also paves the way for children with complex vascular anomalies—once considered unsuitable for transplantation—to be given a second chance through advanced surgical approaches.”

Dialysis is typically performed through either a fistula or venous access, but when these options are absent, a dialysis catheter can be placed. However, since the child had no patent veins that could be accessed from the groin or neck, the catheter was placed through a trans-lumbar approach (gaining access to the body through the lower back) into the inferior vena cava (IVC) above the kidney. This allowed the team to successfully dialyse the child for several months prior to the renal transplant. With the successful completion of the re-transplant, and the new kidney functioning well, the dialysis catheter is scheduled to be removed in a month.

Professor CM Thiagarajan, a senior nephrologist who was treating the child initially, said, “This case exemplifies how innovation and collaboration can redefine what’s possible in paediatric transplantation.”

Tirupati: 08^th May, 2025: Ankura Hospital, Tirupati, achieved a rare medical milestone by successfully performing a laparoscopic appendectomy on a 6-month-old infant diagnosed with an appendicular abscess—an uncommon condition in infants under one year of age.

Baby Zaria was brought to the Pediatric Emergency Department of Ankura Hospital with complaints of excessive crying and multiple episodes of vomiting. Prompt medical evaluation was initiated, and an immediate abdominal ultrasound conducted by the in-house radiologist suggested an appendicular abscess. A subsequent CT scan confirmed an inflamed appendix with localized abscess formation.

In light of the findings, the case was swiftly referred to the pediatric surgical team. Within a few hours of admission, the infant was taken up for a laparoscopic appendectomy. Post-surgery, Zaria was closely monitored in the Pediatric Intensive Care Unit (PICU) for 24 hours. Oral feeding was gradually reintroduced, with no recurrence of vomiting or other complications.

On the third day post-admission, the baby was discharged in stable condition with oral medications and follow-up advice.

“This is a rare and complex presentation in such a young infant, and the timely diagnosis and multidisciplinary coordination were critical to the successful outcome,” said Dr. Vamsi Krishna, Medical Director, Ankura Hospital, Tirupati. “Ankura Hospital provides specialized, evidence-based care for women and children, driven by a team of highly skilled and experienced professionals.”

The case underscores the hospital’s commitment to delivering advanced pediatric surgical care with precision and compassion. The close collaboration between pediatricians, radiologists, and surgeons ensured swift intervention, reinforcing Ankura Hospital’s standing as a trusted center for pediatric excellence.

Bengaluru, 08 May 2025: Aster DM Healthcare, one of the largest integrated healthcare providers in India, announces the signing of a lease agreement to establish its 4^th Multispecialty Hospital in Bengaluru. This 430-bed state-of-the-art facility to come up in Sarjapur is set to revolutionize healthcare in the region with its comprehensive and specialized medical services. Aster DM Healthcare will be making an investment of around INR 480 crores in this facility spreading over 4 lakh sq ft. The first phase of the project with 300 beds will be operational by the second half of FY27 and the remaining 130 beds in FY29. With the establishment of its fourth hospital in Bengaluru, Aster will strategically achieve a city-wide presence, covering all major zones and solidify its position among the top three hospital chains in the city.

Dr. Azad Moopen, Founder & Chairman, Aster DM Healthcare

Sarjapur Road is rapidly emerging as Bengaluru’s next major IT hub, driven by robust infrastructure development and strategic location advantages. The Karnataka Industrial Areas Development Board (KIADB) has announced plans to develop a state-of-the-art IT hub spread across 1,050 acres. This development is complemented by a surge in approved residential and commercial projects, positioning Sarjapur as a high-growth corridor. Its proximity to established IT zones like Whitefield, ORR, and Marathahalli, and a proposed Metro line in Phase 3, further enhances its appeal.

Dr. Azad Moopen, Founder & Chairman, Aster DM Healthcare said, “We are delighted to share the announcement of our forthcoming 430 bed hospital in Sarjapur, a key addition to our growing network and a milestone in our Bengaluru expansion journey. This state-of-the-art facility is being designed to deliver world-class, patient-centric care and will cater to the rapidly growing healthcare needs of the region. As part of our broader vision to strengthen our footprint in key urban centers, the upcoming hospital reinforces our commitment to enhancing access to advanced medical services. Notably, this will be a comprehensive multi-specialty hospital in the South-East Bengaluru micro market, with a focus on cancer care, establishing a strong oncology footprint from inception. With Sarjapur’s growing prominence, we believe this facility will become a cornerstone in our efforts to redefine quality healthcare in Bengaluru. With the addition of this fourth hospital in the city, Aster now establishes a robust presence across the city not only solidifying our position as a leading healthcare provider in the city but also strengthening our leadership in the southern healthcare market.”

Mumbai, May 08, 2025: Dr. Rachita Dhurat, renowned dermatologist and trichologist, has been invited as the only Indian speaker at the prestigious 21st European Hair Research Society (EHRS) Meeting, to be held in Warsaw, Poland from 29–31 May 2025. Dr. Dhurat, Professor and Head of Dermatology at LTMG Hospital and Director of RD Clinic, will present challenging hair cases from India and contribute to global discussions on hair disorders and advanced therapies, marking a proud moment for Indian dermatology.

“It is a true honour to represent India at EHRS 2025. I look forward to sharing unique clinical experiences from India and engaging with the world’s leading experts in hair science. Together, we can advance the understanding and treatment of hair disorders globally,” said Dr. Rachita Dhurat

European Hair Research Society (EHRS) 2025, held in the vibrant city of Warsaw, Poland is a key international event dedicated to promoting research in hair biology and hair diseases, bringing together top experts from around the world to foster collaboration and innovation in trichology.